arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

ZEVRA THERAPEUTICS, INC.

ZVRA
$10.54 ▼ -0.63 (-5.64%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
53 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
57
Health
Fair
Bullish
auto_awesome

Analytical Summary

ZEVRA THERAPEUTICS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $626.2M
Dividend Yield —
Revenue Growth 44.9% ↘
Op. Margin 30.7% ↘
ROIC 4.7% ↘
FCF / Share $0.17 ↘
Trailing P/E 34.0x
Price / Book 2.6x
FCF Yield 1.6%
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Nov 5, 2026.

53-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$37.76M
↑ +44.9% —
Net Income Profit after all expenses
$37.89M
— 0.0% —
Operating Margin Operating profit as % of sales
30.7%
↓ -27.5% 4th
FCF / Share Free cash flow per share
$0.17
↓ -41.9% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
41
Returns
97
Financial Health
43
Cash Quality ↑
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 14 years · 53 quarters